More from the Author

• Case | HBS Case Collection | March 2019 (Revised April 2019)

  Gilead: Hepatitis C Access Strategy (A) (Abridged)

  V. Kasturi Rangan, Vikram Rangan and David E. Bloom

  Gilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of this was accomplished through generic licensing, which brought a $10,000/year treatment regimen down to $100! Should the company replicate that strategy for Hepatitis C? If so, how would its US Healthcare customers, who were paying $84,000 per patient, react? On the other hand, Gilead had to balance the interests of its shareholders, who paid $11 billion for an acquisition that led to the new Hepatitis C drug.

  Keywords: healthcare; Pharmaceuticals; pricing; Access to care; Emerging Markets; Health Care and Treatment; Price; Strategy; Ethics; Health Industry; Pharmaceutical Industry;

  Citation:

  Rangan, V. Kasturi, Vikram Rangan, and David E. Bloom. "Gilead: Hepatitis C Access Strategy (A) (Abridged)." Harvard Business School Case 519-077, March 2019. (Revised April 2019.)  View Details

  CiteView DetailsEducators

  Related

• Case | HBS Case Collection | September 2016 (Revised February 2019)

  KaBOOM!: Play at Scale (A)

  V. Kasturi Rangan and Sarah Appleby

  A case on scaling social impact for nonprofits. Founded in 1995, KaBOOM! quickly became a nationally recognized nonprofit in building playgrounds with strong corporate partnerships and volunteer-organizing capabilities. Over the years, KaBOOM! developed new programs, including a new web platform to enable individuals and communities to do build-it-yourself playgrounds which increased KaBOOM!'s total annual number of playgrounds built by as much as a factor of 10. The case explores how KaBOOM! evaluated its goals and determined a strategy to achieve the scale required to meet its social mission and vision of every child having a place to play.

  Keywords: scaling social impact; scaling; nonprofit scaling; Nonprofit Organizations; Corporate Social Responsibility and Impact; Social Enterprise; Growth and Development Strategy; United States;

  Citation:

  Rangan, V. Kasturi, and Sarah Appleby. "KaBOOM!: Play at Scale (A)." Harvard Business School Case 517-025, September 2016. (Revised February 2019.)  View Details

  CiteView DetailsEducatorsPurchase

  Related

• Case | HBS Case Collection | March 2018 (Revised January 2019)

  Gilead Mexico

  Michael Chu and V. Kasturi Rangan

  With a breakthrough cure for Hepatitis C listing in the U.S. at $1,000/pill, Gilead must now solve the issue of making it available to patients across the world, much as it did for its blockbuster HIV/AIDS antiretrovirals. For Erik Musalem, the new general manager of Gilead Mexico, the challenge was complicated by operating in a middle-income country, where Gilead’s terms for more vulnerable nations did not apply. For all practical purposes, Musalem had only one customer for his company’s Hep C medicine: Mexico’s public health system and the National Pricing Commission that set prices annually for the entire sector. With no lack of priorities competing for the finite resources of the public health sector, Musalem’s charge was to devise the strategy that in the long run would maximize access to the cure in Mexico while protecting the financial strength of Gilead Sciences, Inc.

  Keywords: Health Care and Treatment; Price; Strategy; Management; Pharmaceutical Industry; Mexico;

  Citation:

  Chu, Michael, and V. Kasturi Rangan. "Gilead Mexico." Harvard Business School Case 318-111, March 2018. (Revised January 2019.)  View Details

  CiteView DetailsEducatorsPurchase

  Related